Literature DB >> 20043031

Orphan products: an emerging trend in drug approvals.

Timothy Coté, Aditya Kelkar, Kui Xu, M Miles Braun, M Ian Phillips.   

Abstract

Mesh:

Year:  2010        PMID: 20043031     DOI: 10.1038/nrd2546-c1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  Adopting orphan drugs--two dozen years of treating rare diseases.

Authors:  Marlene E Haffner
Journal:  N Engl J Med       Date:  2006-02-02       Impact factor: 91.245

2.  Market incentives and pharmaceutical innovation.

Authors:  Wesley Yin
Journal:  J Health Econ       Date:  2008-02-17       Impact factor: 3.883

  2 in total
  7 in total

Review 1.  The productivity crisis in pharmaceutical R&D.

Authors:  Fabio Pammolli; Laura Magazzini; Massimo Riccaboni
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

Review 2.  An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences.

Authors:  Aaron S Kesselheim
Journal:  Milbank Q       Date:  2011-09       Impact factor: 4.911

3.  Introduction to a supplement on innovative approaches to studying health outcomes in rare diseases.

Authors:  Aaron S Kesselheim; Joshua J Gagne
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

Review 4.  Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.

Authors:  Elizabeth A Ottinger; Mark L Kao; Nuria Carrillo-Carrasco; Nicole Yanjanin; Roopa Kanakatti Shankar; Marjo Janssen; Marcus Brewster; Ilona Scott; Xin Xu; Jim Cradock; Pramod Terse; Seameen J Dehdashti; Juan Marugan; Wei Zheng; Lili Portilla; Alan Hubbs; William J Pavan; John Heiss; Charles H Vite; Steven U Walkley; Daniel S Ory; Steven A Silber; Forbes D Porter; Christopher P Austin; John C McKew
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

5.  Orphan drug: Development trends and strategies.

Authors:  Aarti Sharma; Abraham Jacob; Manas Tandon; Dushyant Kumar
Journal:  J Pharm Bioallied Sci       Date:  2010-10

6.  The availability and affordability of orphan drugs for rare diseases in China.

Authors:  Shiwei Gong; Yingxiao Wang; Xiaoyun Pan; Liang Zhang; Rui Huang; Xin Chen; Juanjuan Hu; Yi Xu; Si Jin
Journal:  Orphanet J Rare Dis       Date:  2016-02-27       Impact factor: 4.123

7.  Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs.

Authors:  Kojiro Maeda; Masayuki Kaneko; Mamoru Narukawa; Teruyo Arato
Journal:  Orphanet J Rare Dis       Date:  2017-08-23       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.